For example, MDM2 amplification is a diagnostic hallmark in liposarcoma [9], CCND1 amplification is a suspected predictor of resistance against hormone therapy in breast cancer [10], MYC amplification is a strong prognostic marker in breast cancer and other tumors [11], MYCN amplification is an established prognostic marker in neuroblastoma [12], and HER2/EGFR are established therapeutic targets that are often overexpressed as a consequence of gene amplification [13,14]. This evidence concerns the gene MDM2 and breast cancer.